The online version of this article (https://doi.org/10.1186/s12931-017-0713-8) contains supplementary material, which is available to authorized users.
Results have been previously presented as a poster presentation by Dr. Laguna at the North American Cystic Fibrosis Conference 2015 (Phoenix, AZ).
There are urgent needs for clinically relevant biomarkers to identify children with cystic fibrosis (CF) at risk for more progressive lung disease and to serve as outcome measures for clinical trials. Our objective was to investigate three targeted biomarkers in a population of asymptomatic CF infants.
Urine, blood and lung function data were collected for 2 years from clinically stable infants diagnosed with CF by newborn screening. A subset of CF infants had bronchoscopy with lavage performed at 6 months and 1 year. Urine was collected quarterly from healthy control infants. Expectorated sputum and urine were collected quarterly for 2 years from clinically stable CF adults. Desmosine, club cell secretory protein (CCSP) and cathepsin B concentrations were measured and compared. Mixed effects models were used to identify associations between biomarker concentrations and clinical characteristics. Receiver operator characteristic curves were generated to investigate the sensitivity and specificity of the biomarkers.
Urinary cathepsin B was significantly higher in CF infants compared to healthy infants (p = 0.005). CF infant airway and urinary cathepsin B concentrations were significantly lower compared to adult CF subjects (p = 0.002 & p = 0.022, respectively). CF infant airway CCSP was significantly higher than adult CF subjects (p < 0.001). There was a significant correlation between CF infant plasma CCSP and BALF CCSP (p = 0.046). BALF CCSP was negatively associated with IL-8 (p = 0.017). There was no correlation between biomarker concentration and FEV0.5.
Cathepsin B and CCSP show promise as biomarkers of inflammation in CF infants. Further study is needed.
Additional file 1: Cumulative data for targeted biomarkers in healthy control and CF infants. (PDF 49 kb)12931_2017_713_MOESM1_ESM.pdf
Additional file 2: Plot of urinary cathepsin B concentration vs. urinary desmosine concentration. (JPEG 157 kb)12931_2017_713_MOESM2_ESM.jpg
Additional file 3: Additional plots of inflammatory marker analysis. (JPEG 167 kb)12931_2017_713_MOESM3_ESM.jpg
Additional file 4: Table summarizing the culture results for all CF infants. (PDF 34 kb)12931_2017_713_MOESM4_ESM.pdf
Additional file 5: Additional plots of cytokine concentrations in CF infant BALF. (JPEG 134 kb)12931_2017_713_MOESM5_ESM.jpg
Additional file 6: Plots summarizing the statistical analysis of FEV0.5 with targeted biomarkers. (JPEG 159 kb)12931_2017_713_MOESM6_ESM.jpg
Pillarisetti N, Williamson E, Linnane B, Skoric B, Robertson CF, Robinson P, Massie J, Hall GL, Sly P, Stick S, Ranganathan S. Australian respiratory early surveillance team for cystic fibrosis (AREST CF): infection, inflammation, and lung function decline in infants with cystic fibrosis. Am J Respir Crit Care Med. 2011;184(1):75–81. CrossRefPubMed
Mott LS, Park J, Gangell CL, de Klerk NH, Sly PD, Murray CP, Stick SM. Australian respiratory early surveillance team for cystic fibrosis (AREST CF) study group: distribution of early structural lung changes due to cystic fibrosis detected with chest computed tomography. J Pediatr. 2013;
Welsh MJ, Ramsey BW, Accurso FJ, Cutting GR. Cystic fibrosis. In: Anonymous, editor. Cystic fibrosis in the metabolic and molecular basis of inherited disease, vol. 3. 7th ed. New York: McGraw-Hill; 2001. p. 521–88.
Sly PD, Brennan S, Gangell C, de Klerk N, Murray C, Mott L, Stick SM, Robinson PJ, Robertson CF, Ranganathan SC. Australian respiratory early surveillance team for cystic fibrosis (AREST-CF): lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med. 2009;180(2):146–52. CrossRefPubMed
Ramsey KA, Schultz A, Stick SM. Biomarkers in Paediatric cystic fibrosis lung disease. Paediatr Respir Rev. 2015;16(4):213–8. PubMed
Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med. 1995;151(4):1075–82. PubMed
Stoltz DA, Meyerholz DK, Pezzulo AA, Ramachandran S, Rogan MP, Davis GJ, Hanfland RA, Wohlford-Lenane C, Dohrn CL, Bartlett JA, Nelson GA 4th, Chang EH, Taft PJ, Ludwig PS, Estin M, Hornick EE, Launspach JL, Samuel M, Rokhlina T, Karp PH, Ostedgaard LS, Uc A, Starner TD, Horswill AR, Brogden KA, Prather RS, Richter SS, Shilyansky J, McCray PB Jr, Zabner J, Welsh MJ. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci Transl Med. 2010;2(29):29ra31. CrossRefPubMedPubMedCentral
Laguna TA, Williams CB, Nunez MG, Williams CW, Reilly CS, Wendt CH. Biomarkers of early lung disease in infants with cystic fibrosis [abstract]. Pediatr Pulmonol Suppl. 2015;41:274.
Stocks J, Godfrey S, Beardsmore C, Bar-Yishay E, Castile R. ERS/ATS task force on standards for infant respiratory function testing. European Respiratory Society/American Thoracic Society: Plethysmographic measurements of lung volume and airway resistance. ERS/ATS task force on standards for infant respiratory function testing. European Respiratory Society/ American Thoracic Society. Eur Respir J. 2001;17(2):302–12. CrossRefPubMed
American Thoracic Society. European Respiratory Society: ATS/ERS statement: raised volume forced expirations in infants: guidelines for current practice. Am J Respir Crit Care Med. 2005;172(11):1463–71. CrossRef
Saiman L, Siegel JD, LiPuma JJ, Brown RF, Bryson EA, Chambers MJ, Downer VS, Fliege J, Hazle LA, Jain M, Marshall BC, O'Malley C, Pattee SR, Potter-Bynoe G, Reid S, Robinson KA, Sabadosa KA, Schmidt HJ, Tullis E, Webber J, Weber DJ. Cystic fibrous foundation, Society for Healthcare Epidemiology of America: infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol. 2014;35(Suppl 1):S1–S67. CrossRefPubMed
Huang JT, Chaudhuri R, Albarbarawi O, Barton A, Grierson C, Rauchhaus P, Weir CJ, Messow M, Stevens N, McSharry C, Feuerstein G, Mukhopadhyay S, Brady J, Palmer CN, Miller D, Thomson NC. Clinical validity of plasma and urinary desmosine as biomarkers for chronic obstructive pulmonary disease. Thorax. 2012;67(6):502–8. CrossRefPubMedPubMedCentral
R-Core Team: Nlme: linear and nonlinear mixed effects models 2016.
Sagel SD. Identifying novel endpoints for cystic fibrosis clinical trials. Adv Pediatr Infect Dis. 2005;52:115–27.
Bruce MC, Poncz L, Klinger JD, Stern RC, Tomashefski JF Jr, Dearborn DG. Biochemical and pathologic evidence for proteolytic destruction of lung connective tissue in cystic fibrosis. Am Rev Respir Dis. 1985;132(3):529–35. PubMed
Mantile G, Miele L, Cordella-Miele E, Singh G, Katyal SL, Mukherjee AB. Human Clara cell 10-kDa protein is the counterpart of rabbit uteroglobin. J Biol Chem. 1993;268(27):20343–51. PubMed
- Biomarkers of inflammation in infants with cystic fibrosis
Theresa A. Laguna
Cynthia B. Williams
Myra G. Nunez
Catherine E. Moen
Cavan S. Reilly
Chris H. Wendt
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II